---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-005263"
form_type: "8-K"
ticker: "INM"
cik: "0001728328"
company_name: "InMed Pharmaceuticals Inc."
filed_at: "2025-01-22T23:59:59+00:00"
generated_at: "2026-05-27T19:59:05.238673+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# InMed granted first PCT patent in Mexico for novel cannabinoid analog compounds

## Summary
- Patent No. 417531 issued in Mexico; covers novel small molecule compounds and methods of preparation.
- Therapeutic applications include pain, glaucoma, inflammatory disease, anxiety, and neurological conditions like Parkinson's and Alzheimer's.
- Patent holds 20-year term; international application pending in U.S., Europe, Japan, and others.
- InMed now has 14 patent families covering compositions, formulations, manufacturing, and methods of use.
- Compounds are drug candidates for Alzheimer's disease and dry age-related macular degeneration programs.

## SEC filing metadata
- accession: 0001213900-25-005263
- form_type: 8-K
- ticker: INM
- cik: 0001728328
- company_name: InMed Pharmaceuticals Inc.
- filed_at: 2025-01-22T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1728328/000121390025005263/0001213900-25-005263-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1728328/000121390025005263/ea0228337-8k_inmed.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-005263
- JSON: https://secwatch.observer/filing/0001213900-25-005263.json
- Plain text: https://secwatch.observer/filing/0001213900-25-005263.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.